Pfizer (PFE) Goodwill & Intangibles (2009 - 2026)

Pfizer (PFE) has reported Goodwill & Intangibles for 18 consecutive years, with $124.0 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Goodwill & Intangibles rose 1.26% year-over-year to $124.0 billion; the TTM figure through Mar 2026 stood at $124.0 billion (up 1.26% YoY), while the FY2025 annual figure was $125.0 billion, up 0.85% from the prior year.
• Goodwill & Intangibles declined to $124.0 billion in Q1 2026 per PFE's latest filing, from $125.0 billion in the prior quarter.
• Across five years, Goodwill & Intangibles topped out at $132.7 billion in Q4 2023 and bottomed at $79.0 billion in Q3 2022.
• Historically, Goodwill & Intangibles has averaged $113.4 billion across 5 years, with a median of $122.4 billion in 2025.
• Annual changes were most pronounced in 2024 — Goodwill & Intangibles surged 41.34% — and 2025, when it dropped 7.35%.
• Pfizer's Goodwill & Intangibles stood at $94.7 billion in 2022, then surged by 40.04% to $132.7 billion in 2023, then fell by 6.59% to $123.9 billion in 2024, then climbed by 0.85% to $125.0 billion in 2025, then dropped by 0.82% to $124.0 billion in 2026.
• Business Quant data shows PFE's Goodwill & Intangibles at $124.0 billion in Q1 2026, $125.0 billion in Q4 2025, and $120.4 billion in Q3 2025.